Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow.


Journal

Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252

Informations de publication

Date de publication:
05 03 2020
Historique:
entrez: 24 3 2020
pubmed: 24 3 2020
medline: 20 9 2020
Statut: epublish

Résumé

The growing use of medical devices (e.g., vascular grafts, stents, and cardiac catheters) for temporary or permanent purposes that remain in the body's circulatory system demands a reliable and multiparametric approach that evaluates the possible hematologic complications caused by these devices (i.e., activation and destruction of blood components). Comprehensive in vitro hemocompatibility testing of blood-contacting implants is the first step towards successful in vivo implementation. Therefore, extensive analysis according to the International Organization for Standardization 10993-4 (ISO 10993-4) is mandatory prior to clinical application. The presented flow loop describes a sensitive model to analyze the hemostatic performance of stents (in this case, neurovascular) and reveal adverse effects. The use of fresh human whole blood and gentle blood sampling are essential to avoid the preactivation of blood. The blood is perfused through a heparinized tubing containing the test specimen by using a peristaltic pump at a rate of 150 mL/min at 37 °C for 60 min. Before and after perfusion, hematologic markers (i.e., blood cell count, hemoglobin, hematocrit, and plasmatic markers) indicating the activation of leukocytes (polymorphonuclear [PMN]-elastase), platelets (β-thromboglobulin [β-TG]), the coagulation system (thombin-antithrombin III [TAT]), and the complement cascade (SC5b-9) are analyzed. In conclusion, we present an essential and reliable model for extensive hemocompatibility testing of stents and other blood-contacting devices prior to clinical application.

Identifiants

pubmed: 32202530
doi: 10.3791/60610
doi:

Substances chimiques

Biomarkers 0
beta-Thromboglobulin 0
Heparin 9005-49-6
Complement System Proteins 9007-36-7
Pancreatic Elastase EC 3.4.21.36

Types de publication

Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Antonia Link (A)

Department of Thoracic, Cardiac and Vascular Surgery, University Hospital Tuebingen.

Giorgio Cattaneo (G)

Acandis GmbH; Institute of Biomedical Engineering, University of Stuttgart.

Eduard Brynda (E)

Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic.

Tomas Riedel (T)

Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic.

Johanka Kucerova (J)

Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic.

Christian Schlensak (C)

Department of Thoracic, Cardiac and Vascular Surgery, University Hospital Tuebingen.

Hans Peter Wendel (HP)

Department of Thoracic, Cardiac and Vascular Surgery, University Hospital Tuebingen.

Stefanie Krajewski (S)

Department of Thoracic, Cardiac and Vascular Surgery, University Hospital Tuebingen.

Tatjana Michel (T)

Department of Thoracic, Cardiac and Vascular Surgery, University Hospital Tuebingen; tatjana.michel@uni-tuebingen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH